Euroapi

Euroapi Accounts Payable

The Accounts Payable of Euroapi (EAPI.PA) as of Nov 4, 2026 is 110.50 M EUR. In the previous year, Accounts Payable was 104.90 M EUR — a change of 5.34% (higher).

Accounts Payable

110.50 MEUR

YoY

5.34%

Last updated:

Accounts Payable of Euroapi is 2025 110.50 M EUR. Accounts Payable of Euroapi was 2024 104.90 M EUR. It decreases by 5.34% higher compared to the previous year.

The Euroapi Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
120.40 M EUR
Jan 1, 2020
131.10 M EUR
Jan 1, 2021
189.60 M EUR
Jan 1, 2022
219.60 M EUR
Jan 1, 2023
159.60 M EUR
Jan 1, 2024
104.90 M EUR
Jan 1, 2025
110.50 M EUR
The Euroapi Accounts Payable history
YEARAccounts PayableYoY
110.50 MEUR+5.34%
104.90 MEUR-34.27%
159.60 MEUR-27.32%
219.60 MEUR+15.82%
189.60 MEUR+44.62%
131.10 MEUR+8.89%
120.40 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA generates revenue by manufacturing and supplying active pharmaceutical ingredient solutions to healthcare companies. The company develops and produces vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates including morphine, codeine, and thebaine, as well as analgesics. It offers Contract Development and Manufacturing Organization (CDMO) services through its Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances technologies. Healthcare partners purchase these products and services, with production sites across France, the United Kingdom, Germany, Italy, and Hungary supporting the supply chain. The company’s primary customers are healthcare companies seeking active pharmaceutical ingredient solutions. These clients buy products like vitamin B12, prostaglandins, and opiates, as well as CDMO services such as Microbial Fermentation and Steroids and Hormones development. Euroapi SA’s revenue streams are derived from both the direct sale of active ingredients and the provision of specialized manufacturing services through its CDMO division. Euroapi SA’s business model relies on its global production network in five countries to deliver tailored pharmaceutical solutions. The firm’s portfolio includes high-demand molecules such as opioids (morphine, codeine, thebaine) and hormone-based treatments, which are supplied to healthcare partners through its CDMO services. This dual approach of product sales and service-based manufacturing ensures steady revenue from established pharmaceutical markets. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

Accounts Payable of Euroapi is 110.50 M EUR in 2025.

Accounts Payable of Euroapi changed from 104.90 M EUR to 110.50 M EUR, representing a 5.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Euroapi since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Euroapi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Euroapi

All Key Metrics — Euroapi